Last reviewed · How we verify
NCT03437590
A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739
Phase 1 trial testing JNJ-55308942 in Healthy in 13 participants. Completed in 19 October 2018.
19 October 2018
Quick facts
| Lead sponsor | Janssen-Cilag International NV |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 13 |
| Start date | 15 March 2018 |
| Primary completion | 19 October 2018 |
| Estimated completion | 19 October 2018 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- JNJ-55308942 — full drug profile →
- [18F]-JNJ-64413739
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Janssen-Cilag International NV — full company profile →
Who can join
Adults 18 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to measure the blocking of \[18F\]-JNJ-64413739 uptake in the brain at the time to reach maximum plasma concentration (Tmax) and at 24 hours postdose of JNJ-55308942 following a single dose of JNJ-55308942; and to model the exposure/receptor interaction of JNJ-55308942.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Role of NLRP3 Inflammasome in Parkinson's Disease and Therapeutic Considerations.
Nguyen LTN, Nguyen HD, Kim YJ, Nguyen TT, et al · · 2022 · cited 57× · PMID 35988226 · DOI 10.3233/jpd-223290 -
The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke).
Barca C, Foray C, Hermann S, Herrlinger U, et al · · 2021 · cited 49× · PMID 34950148 · DOI 10.3389/fimmu.2021.787307 -
Purine and purinergic receptors in health and disease.
Ai Y, Wang H, Liu L, Qi Y, et al · · 2023 · cited 25× · PMID 37692109 · DOI 10.1002/mco2.359 -
Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?
Schmidt S, Isaak A, Junker A. · · 2023 · cited 18× · PMID 36674884 · DOI 10.3390/ijms24021374 -
Adenosine triphosphate induced cell death: Mechanisms and implications in cancer biology and therapy.
Zhang HL, Sandai D, Zhang ZW, Song ZJ, et al · · 2023 · cited 11× · PMID 38179405 · DOI 10.5306/wjco.v14.i12.549 -
P2 purinergic receptor dysregulation in urologic disease.
Maynard JP, Sfanos KS. · · 2022 · cited 10× · PMID 35687210 · DOI 10.1007/s11302-022-09875-1 -
The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.
Han S, Suzuki-Kerr H, Vlajkovic SM, Thorne PR. · · 2022 · cited 9× · PMID 36173587 · DOI 10.1007/s11302-022-09896-w -
Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [<sup>18</sup>F]JNJ-64413739 PET and MRA-driven image derived input function.
Mertens N, Schmidt ME, Hijzen A, Van Weehaeghe D, et al · · 2021 · cited 9× · PMID 34373571 · DOI 10.1038/s41598-021-95715-y
Verify or expand the search:
- PubMed search for NCT03437590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JNJ-55308942
Trials testing the same drug.
- NCT05328297 — A Study of JNJ-55308942 in the Treatment of Bipolar Depression · Phase 2 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Janssen-Cilag International NV trials
Trials by the same sponsor.
- NCT04940039 — A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings · Phase 4 · completed
- NCT04338321 — A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selectiv · Phase 3 · completed
- NCT03852160 — A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Stan · Phase 3 · withdrawn
- NCT03947814 — A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment · Phase 1 · terminated
- NCT03816631 — A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03437590 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen-Cilag International NV
- Last refreshed: 27 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03437590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing